Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX)
Analysts are sharing conflicting opinions on several healthcare companies, including Design Therapeutics (DSGN), Pro Medicus Limited (PMCUF), and Boston Scientific (BSX). RBC Capital analysts maintained Buy ratings on Design Therapeutics and Boston Scientific, with price targets of $20.00 and $100.00 respectively, while maintaining a Hold rating on Pro Medicus Limited with a target of A$195.00. The consensus for all three stocks remains a Strong Buy with significant potential upside.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow (NASDAQ:DSGN) 2026-05-19
Design Therapeutics, Inc. (DSGN) has released a slideshow discussing data from its RESTORE-FA Trial of DT-216P2, a drug candidate for Friedreich Ataxia. The company published this slide deck in conjunction with the event to provide details on the trial's findings. This report was generated by Seeking Alpha's transcripts team.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics announced positive biomarker and clinical findings from its Phase 1/2 RESTORE-FA trial for DT-216P2, a treatment for Friedreich ataxia. The therapy showed dose-dependent increases in frataxin levels and improved clinical measures, leading to an initial stock surge. However, the stock later fell despite the positive data, with shares down over 28% at publication time.
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich ataxia patients, showing dose-dependent improvements in clinical measures and increased frataxin levels, with the treatment being generally well-tolerated. The company plans to pursue a registrational path for DT-216P2 and is performing strongly in the market, holding more cash than debt and exceeding short-term obligations while analysts revise earnings estimates upward.
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich ataxia patients. The treatment showed improvements in the Friedreich’s Ataxia Rating Scale, Upright Stability Score, and patient-reported fatigue, alongside dose-dependent increases in frataxin. DT-216P2 was well-tolerated, and the company plans to pursue a registrational path, with an update expected in Q4 2026.
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN)
Design Therapeutics (DSGN) shares saw a significant increase following the announcement of encouraging interim results from its Phase 1 multiple-ascending dose clinical trial of DT-216 for Friedreich ataxia. The data showed dose-dependent increases in frataxin protein and improvements in disease relevant biomarkers, with DT-216 being well-tolerated. This positive news suggests potential for a new treatment option for the rare genetic disorder.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics (DSGN) saw its stock surge then fall after releasing positive Phase 1/2 RESTORE-FA trial data for DT-216P2, a treatment for Friedreich ataxia. The drug showed dose-dependent increases in frataxin levels and significant clinical improvements, exceeding expectations for fatigue reduction. Despite the promising data and plans for a registrational path, the stock was down 28.88% at the time of publication.
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk
Design Therapeutics (NASDAQ: DSGN) is experiencing a significant stock decline, with shares down over 25% today. This puts the company on track for its largest percentage decrease since August 2023. This data indicates a notable negative movement in the company's stock performance.
Design Therapeutics reports positive Phase 1/2 DT-216P2 data
Design Therapeutics announced positive early Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich ataxia patients, demonstrating meaningful functional and fatigue improvements, along with robust frataxin biomarker increases. The drug was generally well tolerated, and the company plans to pursue a registrational path with further updates expected in late 2026. Despite positive clinical news, Spark, TipRanks' AI Analyst, rates DSGN as Neutral due to weak financial performance outweighing positive technical momentum and pipeline progress.
Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia
Design Therapeutics (DSGN) has announced positive four-week IV data from its RESTORE-FA trial for DT-216P2. The results demonstrated both clinical improvements and comprehensive biomarker activity in patients with Friedreich Ataxia.
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich ataxia patients, showing improvements in motor function, fatigue, and frataxin levels. The treatment was well-tolerated, and the company plans to pursue a registrational path. This data, along with a strong financial position, has contributed to significant market performance for DSGN.
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics announced positive four-week data from its RESTORE-FA trial for DT-216P2, a treatment for Friedreich ataxia. The GeneTAC® small-molecule therapeutic showed dose-dependent improvements in clinical measures like mFARS and upright stability, as well as significant increases in endogenous frataxin (FXN) mRNA and protein. DT-216P2 was generally well-tolerated, and the company plans to advance it towards registrational development.
Four-week FA trial finds balance and fatigue gains with experimental drug
Design Therapeutics announced positive four-week data from its Phase 1/2 RESTORE-FA trial of DT-216P2 for Friedreich ataxia, reporting significant improvements in balance, fatigue, and frataxin (FXN) levels. Patients at the 1 mpk dose showed mean improvements of 6.4 mFARS points and 2.7 Upright Stability points, with fatigue reductions exceeding the minimal important change. The drug was generally well-tolerated, and the company plans to pursue a registrational path, with an update expected in Q4 2026.
RESTORE-FA data push Design Therapeutics (DSGN) to plan registrational path
Design Therapeutics (DSGN) reported positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich ataxia. Patients at the 1 mpk dose showed significant improvements in ataxia scores, fatigue, and frataxin biomarkers, with the treatment being generally well-tolerated. Based on these promising results, the company plans to pursue a registrational path for DT-216P2 and will provide an update in Q4 2026.
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics (Nasdaq: DSGN) plans to host an investor webcast on Monday, May 18, 2026, at 8:00 a.m. ET to announce data from its ongoing Phase 1/2 RESTORE-FA trial. This trial is evaluating DT-216P2 for the treatment of Friedreich’s ataxia. The webcast will be accessible through the company's website.
Design Therapeutics to Announce Phase 1/2 RESTORE-FA Trial Data for DT-216P2 in Friedreich's Ataxia on May 18, 2026
Design Therapeutics (DSGN) is set to announce Phase 1/2 RESTORE-FA trial data for its Friedreich's ataxia drug, DT-216P2, on May 18, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. This announcement highlights the company's progress in developing treatments for serious genetic diseases using its GeneTAC® technology, with other programs targeting Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 also in development.
Design Therapeutics to Announce Phase 1/2 RESTORE-FA Trial Data for DT-216P2 in Friedreich's Ataxia on May 18, 2026
Design Therapeutics (DSGN) will announce Phase 1/2 RESTORE-FA trial data for its drug DT-216P2 in Friedreich's ataxia on May 18, 2026. The company, which uses GeneTAC® technology to target disease-causing genes, will host a conference call and webcast to discuss the results. This announcement is a significant step in the development of their treatment pipeline for serious genetic diseases.
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51
This article reports that the price target for Design Therapeutics (DSGN) has been increased by 17.05%, bringing it to $17.51. This adjustment indicates a more optimistic outlook for the company's stock value.
Cramer: Design Therapeutics Is ‘Pure Spec,’ Buy This Health Care Stock
Jim Cramer labeled Design Therapeutics (NASDAQ: DSGN) as a "pure spec" stock, warning of high risk but also potential for significant gains. He recommended BillionToOne (NASDAQ: BLLN) as a buy, citing its better-than-expected earnings and raised sales forecast. Cramer also discussed Silicon Motion Technology (NASDAQ: SIMO) and Wynn Resorts (NASDAQ: WYNN), suggesting to buy SIMO on a pull-back and to hold off on WYNN due to ongoing issues in the Gulf.
Point72 (DSGN) discloses 2.72M-share stake, 4.4% ownership
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 2,722,754 shares in Design Therapeutics (DSGN), representing a 4.4% stake as of March 31, 2026. This disclosure is a passive investment, as indicated in their SCHEDULE 13G/A SEC filing, meaning they hold shared voting and dispositive power through investment management arrangements but no direct ownership. The filing is routine, and subsequent changes would be reported if the stake crosses the 5% threshold or if control arrangements change.
Design Therapeutics Q1 2026 Earnings Call Transcript
Design Therapeutics (DSGN) provided an update on its Friedreich's Ataxia (FA) program and the RESTORE-FA study during its Q1 2026 earnings call. CEO Pratik Shah highlighted that the multiple-ascending-dose trial for DT-216 is progressing, with clinical data expected in the second half of 2026. The company is focusing on biomarker endpoints in this early study to inform an accelerated regulatory path, though definitive clinical benefit is not anticipated yet.
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21
Oppenheimer has reiterated its Buy rating on Design Therapeutics (DSGN.US) and increased the price target to $21. This indicates a positive outlook from the firm regarding the company's stock performance and future prospects.
Design Therapeutics Set For Multiple Clinical Trial Catalysts In H2 2026
Design Therapeutics Inc. (DSGN), a clinical-stage biotechnology company, is anticipating several clinical trial catalysts in the second half of 2026. The company focuses on developing GeneTAC drug candidates to treat serious degenerative genetic diseases by targeting the root cause of these conditions. These molecules aim to modulate the activity of faulty genes.
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Moderate Buy" from Analysts
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus "Moderate Buy" rating from seven analysts, with an average 1-year price target of $16.00. Institutional investors, including Baker BROS. Advisors LP, Vivo Capital LLC, and RA Capital Management L.P., have significantly increased their holdings, now owning 56.64% of the company's stock. The biopharmaceutical company, specializing in genetic diseases, recently reported strong quarterly earnings, beating analyst estimates, and has a market capitalization of $830.7 million.
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96
The article reports that the price target for Design Therapeutics (DSGN) has been increased by 12.82%, raising it to $14.96. The content itself seems to be missing and only the title is provided.
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Design Therapeutics (NASDAQ:DSGN) from a "hold" to a "sell" rating. Despite this, the consensus among analysts remains a "Moderate Buy" with an average price target of $16.00. The company recently reported better-than-expected Q1 EPS, and institutional investors have been actively trading its shares.
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H By Investing.com
Design Therapeutics (NASDAQ: DSGN) outlined progress on its GeneTAC® platform and clinical pipeline, targeting rare genetic disorders. The company reported Q1 2026 earnings that surpassed analyst expectations and expects multiple data readouts in the second half of 2026, with its cash position funding operations into 2029. Key programs include treatments for Friedreich Ataxia, Fuchs Endothelial Corneal Dystrophy, Myotonic Dystrophy Type 1, and Huntington’s Disease, all leveraging small molecules to modulate gene transcription.
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat
Design Therapeutics (NASDAQ:DSGN) shares reached a new 52-week high after reporting a Q1 loss per share of ($0.29), beating the consensus estimate of ($0.36) by $0.07. The stock holds a consensus "Moderate Buy" rating with an average target price of $15.20, and institutional investors have significantly increased their holdings, owning about 56.64% of shares. The company actively researches and develops small molecule therapeutic drugs for genetic diseases.
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Wednesday
Design Therapeutics (NASDAQ:DSGN) is scheduled to announce its Q1 2026 earnings after the market closes on Wednesday, May 6th, with analysts projecting a loss of ($0.36) per share. The company's stock recently traded around $12.81, with a market capitalization of approximately $800 million. Analysts currently have a "Moderate Buy" rating for DSGN, with an average price target of $15.20.
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H
Design Therapeutics (NASDAQ:DSGN) delivered an updated overview of its GeneTAC® platform and clinical pipeline, which targets rare genetic disorders. The company reported better-than-expected Q1 2026 earnings and has significant data readouts set for the second half of 2026 across its Friedreich Ataxia, FECD, and DM1 programs. Design Therapeutics believes its small molecule GeneTAC® platform offers advantages over traditional gene therapies due to broader tissue distribution and the ability to modulate endogenous gene expression.
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations
Design Therapeutics (DSGN) reported first-quarter 2026 earnings, exceeding EPS expectations with -$0.29 against a forecast of -$0.32, a 9.38% positive surprise. The company did not disclose revenue, instead emphasizing progress in its RESTORE-FA clinical trial for Friedreich’s Ataxia. The stock remained stable at $12.81 in premarket trading as the company focuses on long-term growth through R&D and anticipates clinical data in the second half of 2026.
Design Therapeutics 1Q Loss/Shr 29c >DSGN
Design Therapeutics reported a first-quarter loss per share of 29 cents. The company's stock symbol is DSGN.
Design Therapeutics Q1 2026 Earnings Call Transcript
Design Therapeutics held its Q1 2026 earnings call, featuring CEO Pratik Shah, who provided an update on the Friedreich's Ataxia (FA) program and the RESTORE-FA study. The company anticipates clinical data in the second half of 2026, focusing on biomarker endpoints rather than definitive clinical benefit in this early-stage study. DT-216, their GeneTAC molecule, aims to increase frataxin mRNA and protein, with early human pharmacokinetic data supporting weekly dosing.
Cash runway into 2029 as Design Therapeutics (NASDAQ: DSGN) advances trials
Design Therapeutics (NASDAQ: DSGN) reported Q1 2026 results, showing a net loss of $17.6 million and cash, cash equivalents, and investment securities totaling $222.8 million, which is projected to fund operations until 2029. The company is progressing with its GeneTAC® pipeline, including ongoing Phase 1/2 trials for Friedreich ataxia, a Phase 2 biomarker trial for Fuchs endothelial corneal dystrophy, and a Phase 1 trial for myotonic dystrophy type-1 expected to start dosing in the first half of 2026. David Shapiro, M.D., was also appointed to the board to enhance clinical and regulatory expertise.
$222.8M gives Design Therapeutics funding into 2029 as trials advance
Design Therapeutics reported its Q1 2026 financial results, closing the quarter with $222.8 million in cash, which is expected to fund operations into 2029. The company highlighted ongoing clinical trials, including the RESTORE-FA multiple-ascending-dose trial for DT-216P2 and a Phase 2 DT-168 biomarker study, with key data readouts anticipated in H2 2026. Additionally, dosing for DT-818 (DM1) is expected to begin in H1 2026, and David Shapiro, M.D., was appointed to the board to enhance clinical and regulatory expertise.
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations
Design Therapeutics (DSGN) reported an EPS of -$0.29 for Q1 2026, exceeding analyst expectations of -$0.32, a 9.38% positive surprise. The company did not disclose revenue, instead focusing on the progress of its RESTORE-FA clinical trial for Friedreich’s Ataxia, with data expected in the second half of 2026. The stock remained stable at $12.81, reflecting cautious optimism despite being considered overvalued by InvestingPro.
Friedreich's Ataxia Pipeline Enters a Transformative Era with
The Friedreich's Ataxia pipeline is undergoing significant transformation with over 20 therapeutic candidates from more than 18 companies, including Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics. These companies are focusing on novel strategies like gene therapy and protein replacement to address genetic and mitochondrial dysfunctions. DelveInsight's report provides a comprehensive analysis of this evolving landscape, highlighting key clinical developments, emerging therapies, and future outlook despite challenges like rare disease populations.
Design Therapeutics (DSGN) details 2026 annual meeting, director vote and auditor ratification
Design Therapeutics (DSGN) has announced its 2026 virtual annual meeting of stockholders to be held on June 9, 2026. Stockholders will vote on the election of Simeon George, M.D. as a Class II director and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2026. The proxy statement also details executive compensation for 2025, board structure, and corporate governance policies.
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week High - Still a Buy?
Design Therapeutics (NASDAQ:DSGN) recently reached a new 52-week high of $13.54, trading around $13.27. Despite a mixed but generally positive analyst sentiment with a "Moderate Buy" consensus and an average target price of $15.20, the company still maintains a negative P/E ratio. Institutional investors hold approximately 56.64% of the stock, and the company recently beat its quarterly EPS estimates.
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - Should You Buy?
Design Therapeutics (NASDAQ:DSGN) recently hit a new 52-week high of $12.98, trading at $12.9240 with a market capitalization of approximately $776.4 million. The company reported a Q4 EPS of ($0.27), exceeding estimates, and analysts have a "Moderate Buy" consensus with an average price target of $15.20. Institutional investors hold a significant 56.64% stake in the company.
DSGN Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for DSGN, including upcoming revenue and EPS estimates, historical stock price reactions to earnings reports, and an AI analysis of past performance. It also touches on analyst revisions and investor sentiment surrounding the company's financial outlook.
DSGN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Design Therapeutics Inc's (DSGN) financial performance, focusing on its profitability and a comparison with competitors. While the company's gross, operating, and net margins are not available, it reports a Return on Equity (ROE) of -30.70%. DSGN, with a market capitalization of $692.58M, is benchmarked against ANRO and ARVN to assess its financial standing within the market.
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - Here's What Happened
Design Therapeutics (NASDAQ:DSGN) reached a new 52-week high of $11.30, trading up approximately 2% on Thursday. The company reported better-than-expected Q1 EPS and has a "Moderate Buy" consensus rating from analysts with an average price target of $15.20. Institutional investors hold a significant portion of the stock, and the company is developing small molecule therapeutic drugs for genetic diseases.
Design Therapeutics, Inc. Appoints David Shapiro, M.D. as Class III Director and as Nominating and Corporate Governance Committee Member, Effective March 31, 2026
Design Therapeutics, Inc. announced the appointment of David Shapiro, M.D., to its Board of Directors as a Class III director, effective March 31, 2026. Dr. Shapiro will also serve on the Nominating and Corporate Governance Committee, with his term as director concluding at the company's 2027 annual meeting of stockholders.
Design Therapeutics (DSGN) director David Shapiro submits Form 3
Design Therapeutics, Inc. director David Shapiro has submitted a Form 3, which is an initial statement of beneficial ownership of securities. This filing registers his status as a reporting person with the SEC. The Form 3 indicates no reportable transactions or holdings, meaning it solely serves to acknowledge his director position without disclosing any current share ownership or trading activity.
Director David Shapiro granted 67,500 DSGN stock options (DSGN)
Design Therapeutics director David Shapiro was granted 67,500 new stock options. These options include a grant for 60,000 shares vesting over 36 months and another for 7,500 shares vesting over 12 months, both with an exercise price of $10.64 and expiring on March 30, 2036. This transaction represents compensation awards rather than open-market trading.
David Shapiro joins Design Therapeutics (DSGN) board with equity awards
Design Therapeutics, Inc. announced the appointment of David Shapiro, M.D., to its Board of Directors as a Class III director, effective March 31, 2026. Dr. Shapiro will also serve on the Nominating and Corporate Governance Committee. His compensation includes an annual cash retainer for Board and committee service, along with significant equity awards including an initial option to purchase 60,000 shares and a prorated annual option for 7,500 shares.
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96
The article reports that Design Therapeutics (DSGN) has experienced a 12.82% increase in its price target, raising it to $14.96. The content itself is not available, but the headline indicates a positive adjustment in analyst expectations for the company's stock.
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
This DelveInsight report analyzes the Fuchs Dystrophy pipeline landscape for 2026, highlighting over five key companies developing new treatment therapies. It covers clinical trials, therapy mechanisms, and FDA updates, noting significant emerging therapies like K-321, TTHX1114, and DT-168. The report also details a recent Phase I trial by Design Therapeutics for DT-168, showing favorable safety and tolerability results for Fuchs endothelial corneal dystrophy (FECD).
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
A DelveInsight report indicates that over five companies are actively developing more than five treatment therapies for Fuchs Dystrophy, a progressive eye disease affecting the cornea. Key companies like Kowa Pharmaceutical, Trefoil Therapeutics, and Design Therapeutics are advancing therapies such as K-321, TTHX1114, and DT-168 through various clinical trial stages. Design Therapeutics recently announced positive Phase I trial results for DT-168, an eye drop designed to reduce mutant TCF4 gene expression associated with the condition.
